Literature DB >> 1490033

Modulatory effect of prolactin on the resting and mitogen-induced activity of T, B, and NK lymphocytes.

L Matera1, A Cesano, G Bellone, E Oberholtzer.   

Abstract

Prolactin (PRL) has been shown to contribute to the development of lymphoid tissues and maintenance of physiological immune function. Here we show that the role of the hormone extends to the control of the effector phase of the immune response. In addition to triggering resting lymphocytes to cell division, the hormone can also control the magnitude of their response to polyclonal stimuli. Concentrations of PRL in the physiological range increased the [3H]thymidine, [3H]uridine, and [3H]leucine incorporation of unstimulated NK cells cultured in serum-free conditions. The same concentrations of the hormone increased the response of NK, T, and B cells to the mitogenic stimuli interleukin 2 (IL2), phytohemagglutinin (PHA), and staphylococcus aureus cowan, respectively, the effect being maximally evident in the presence of suboptimal concentrations of the mitogens. By contrast concentrations of PRL five- to tenfold the physiological levels inhibited the mitogenic response to IL2 and PHA. These data indicate a double-faceted regulatory role of this hormone in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1490033     DOI: 10.1016/0889-1591(92)90039-q

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  18 in total

1.  Prolactin-regulated pim-1 transcription: identification of critical promoter elements and Akt signaling.

Authors:  Nithya Krishnan; Huiqi Pan; Donna J Buckley; Arthur Buckley
Journal:  Endocrine       Date:  2003 Feb-Mar       Impact factor: 3.633

2.  Relationship between 17-beta-estradiol and prolactin in the regulation of natural killer cell activity during progression of endometriosis.

Authors:  M Provinciali; G Di Stefano; M Muzzioli; G G Garzetti; A Ciavattini; N Fabris
Journal:  J Endocrinol Invest       Date:  1995-09       Impact factor: 4.256

Review 3.  Seasonal changes in vertebrate immune activity: mediation by physiological trade-offs.

Authors:  Lynn B Martin; Zachary M Weil; Randy J Nelson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-01-27       Impact factor: 6.237

4.  Role of prolactin in the in vitro development of interleukin-2-driven anti-tumoural lymphokine-activated killer cells.

Authors:  L Matera; G Bellone; J J Lebren; P A Kelly; E L Hooghe Peters; P F Di Celle; R Foa; M Contarini; G Avanzi; V Asnaghi
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

Review 5.  Minireview: prolactin regulation of adult stem cells.

Authors:  Lucila Sackmann-Sala; Jacques-Emmanuel Guidotti; Vincent Goffin
Journal:  Mol Endocrinol       Date:  2015-03-20

Review 6.  The role of prolactin in the pathogenesis of autoimmune disease.

Authors:  Istvan Berczi
Journal:  Endocr Pathol       Date:  1993-12       Impact factor: 3.943

Review 7.  Protein hormones and immunity.

Authors:  Keith W Kelley; Douglas A Weigent; Ron Kooijman
Journal:  Brain Behav Immun       Date:  2007-01-02       Impact factor: 7.217

8.  Up-modulation of interferon-gamma mediates the enhancement of spontanous cytotoxicity in prolactin-activated natural killer cells.

Authors:  L Matera; M Contarini; G Bellone; B Forno; A Biglino
Journal:  Immunology       Date:  1999-11       Impact factor: 7.397

9.  Prolactin promotes cartilage survival and attenuates inflammation in inflammatory arthritis.

Authors:  Norma Adán; Jessica Guzmán-Morales; Maria G Ledesma-Colunga; Sonia I Perales-Canales; Andrés Quintanar-Stéphano; Fernando López-Barrera; Isabel Méndez; Bibiana Moreno-Carranza; Jakob Triebel; Nadine Binart; Gonzalo Martínez de la Escalera; Stéphanie Thebault; Carmen Clapp
Journal:  J Clin Invest       Date:  2013-08-01       Impact factor: 14.808

10.  Role of prolactin receptor and CD25 in protection of circulating T lymphocytes from apoptosis in patients with breast cancer.

Authors:  T Bauernhofer; I Kuss; U Friebe-Hoffmann; A S Baum; G Dworacki; B K Vonderhaar; T L Whiteside
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.